Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 05, 2024 07:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Reports Q3 2024 Business Highlights

WOBURN, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine months ended September 30, 2024. The...
August 06, 2024 07:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Reports Q2 2024 Business Highlights and Update on Review of Strategic Options

NeuroMetrix, Inc. today reported financial and business highlights for the quarter and six months ended June 30, 2024.
February 15, 2024 09:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference Call

NeuroMetrix plans to issue its 2023 fourth quarter and year end business and financial highlights before the opening of the market on February 22, 2024.
February 13, 2024 09:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value

WOBURN, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO), a commercial stage medical device company focused on reducing the impact of neurological disorders and pain...
December 12, 2023 09:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)

NeuroMetrix reported the recent presentation of data from a clinical trial of Quell wearable neuromodulation technology in patients with Long COVID.
December 05, 2023 09:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)

NeuroMetrix noted publication of results from a NIH-funded clinical trial of Quell. The paper has been electronically published in The Journal of Pain.
October 23, 2023 11:13 ET | Source: NeuroMetrix, Inc.

NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference Call

NeuroMetrix, Inc. announced today that it plans to issue its Q3 2023 business and financial highlights on October 26, 2023 at 8:00 a.m., Eastern Time.
May 31, 2023 09:00 ET | Source: NeuroMetrix, Inc.

Quell® Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy (CIPN)

WOBURN, Mass., May 31, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) noted publication of an abstract describing partial results from a NIH-funded, multi-site randomized controlled trial...
May 03, 2023 07:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix Reports Q1 2023 Financial Results

WOBURN, Mass., May 03, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended March 31, 2023. The Company’s mission is to...
March 21, 2023 09:00 ET | Source: NeuroMetrix, Inc.

NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting

WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...